Dr. Samir N. Khleif is an intentionally recognized transformational leader in health care, academic and research-based institutions. His leadership roles spanned developing and leading successful and complex trans and inter-disciplinary educational and academic, research and clinical health care systems at institutions in the US and internationally. Further, he is a nationally recognized leader in precision medicine targeted-therapy and immunotherapy of cancer.
Dr. Khleif is currently the Director of Georgia Cancer Center, a Professor of Medicine, and a Professor of Biochemistry and Cancer Biology at the Medical College of Georgia, a Professor of Graduate Studies at the Georgia Regents University and a Georgia Research Alliance Distinguished Cancer physician and scientist. Dr. Khleif previously served as the Chief of the Cancer Vaccine Section at National Cancer Institute (NCI), a Professor of Medicine at the Uniformed Services University of the Health Sciences and as a Special Assistant to the Commissioner of the Food and Drug Administration (FDA) from 2006-2009, when he also led the Critical Path Initiative for Oncology.
During his tenure at the NCI, Dr. Khleif was tasked by the US government to develop and lead the King Hussein Cancer Center in Jordan, where he served as director from 2002-2006. He also served as Director of the King Hussein Cancer and Biotechnology Institute from 2006-2009. He has led numerous national and international efforts on the development of biomarkers and integration of biomarkers in clinical trials, including the AACR-NCI-FDA Cancer Biomarker Collaborative and the ASCO Alternative Clinical Trial Design.
Dr. Khleif authored numerous books, chapters, and scientific articles on tumor immunology and the development process of biomarkers. Dr. Khleif was inducted into the American Society for Clinical Investigation, he received the National Cancer Institute’s Director Golden Star Award, the National Institutes of Health Award for Merit, the Commendation Medal of the US Public Health Service and he was appointed to the Institute of Medicine National Cancer Policy Forum. He currently chairs the NRG Cooperative Group Immune Therapy Committee and was recently elected a member of the Board of the Society of Immune Therapy of Cancer.
Dr. Khleif received his MD from the University of Jordan in Amman, Jordan, and completed a fellowship in Medical Oncology at the NCI in Bethesda, Maryland.
Healthcare (Clinical Cancer) Operations; Academic Medicine Administration; Research & Clinical Trials Administration; Biotech Development